Study: NCT02023255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39393406
Description: In Part A of the study, participants will receive single dose of JNJ-39393406 50 mg, 150 mg, 450 mg, 1,350 mg, and 2,700 mg once daily for 7 consecutive days. In Part B of the study, participants will receive single dose of JNJ-39393406 based on the PK data from Part A of the study once daily for 13 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39393406
Description: In Part A of the study, participants will receive single dose of JNJ-39393406 50 mg, 150 mg, 450 mg, 1,350 mg, and 2,700 mg once daily for 7 consecutive days. In Part B of the study, participants will receive single dose of JNJ-39393406 based on the PK data from Part A of the study once daily for 13 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39393406
Description: In Part A of the study, participants will receive single dose of JNJ-39393406 50 mg, 150 mg, 450 mg, 1,350 mg, and 2,700 mg once daily for 7 consecutive days. In Part B of the study, participants will receive single dose of JNJ-39393406 based on the PK data from Part A of the study once daily for 13 consecutive days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: In Part A of the study, participants will receive placebo for 7 consecutive days and in Part B of the study, participants will receive placebo for 13 consecutive days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: In Part A of the study, participants will receive placebo for 7 consecutive days and in Part B of the study, participants will receive placebo for 13 consecutive days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: In Part A of the study, participants will receive placebo for 7 consecutive days and in Part B of the study, participants will receive placebo for 13 consecutive days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: In Part A of the study, participants will receive placebo for 7 consecutive days and in Part B of the study, participants will receive placebo for 13 consecutive days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: In Part A of the study, participants will receive placebo for 7 consecutive days and in Part B of the study, participants will receive placebo for 13 consecutive days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: In Part A of the study, participants will receive placebo for 7 consecutive days and in Part B of the study, participants will receive placebo for 13 consecutive days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: In Part A of the study, participants will receive placebo for 7 consecutive days and in Part B of the study, participants will receive placebo for 13 consecutive days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: In Part A of the study, participants will receive placebo for 7 consecutive days and in Part B of the study, participants will receive placebo for 13 consecutive days.